IDEAYA Q1 2023: $351.2M cash, darovasertib 45% ORR in 1L MUM, starting Phase 2/3

IDEAYA Biosciences, Inc.

2023-Q1 EPS reported -$0.49 revenue$7,880,000

Cash, equivalents & marketable securities $351.2M as of Mar 31, plus $188.7M net from Apr offering, funding into 2027.
Darovasertib + crizotinib Phase 2: 45% ORR, 90% DCR, ~7 mo median PFS in 1L MUM; 30% ORR any-line MUM.
Initiating Phase 2/3 registrational trial in 1L HLA-A2(-) MUM in Q2 2023 with median PFS primary endpoint.
Neoadjuvant darovasertib case: ~80% ocular tumor shrinkage, avoided enucleation, restored 6/5 vision.
IDE161 first cohort enrolled in Phase 1; Pol Theta Helicase IND targeted Q2 2023 ($7M GSK milestone).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IDEAYA Biosciences, Inc. reported financial results for the first quarter ended March 31, 2023.

Period: the first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 9, 2023, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

View on SEC.gov

Browse all earnings releases →

IDEAYA Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-019083

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.